Previous 10 | Next 10 |
2023-08-06 17:35:15 ET More on the markets Charts Say Pullback Should Be Followed By Higher Highs SPY: It's Time To Book Some Profits (Technical Analysis, Rating Downgrade) 3 Reasons Why SPY Could Be On The Cusp Of A Bear Market Roth MKM still sees recession ...
2023-08-01 11:50:03 ET Incyte Corporation (INCY) Q2 2023 Earnings Call Transcript July 31, 2023 08:00 AM ET Company Participants Greg Shertzer - Investor Relations Herve Hoppenot - President and Chief Executive Officer Pablo Cagnoni - President, Head of Research ...
2023-08-01 07:04:04 ET Incyte press release ( NASDAQ: INCY ): Q2 Non-GAAP EPS of $0.99 beats by $0.12 . Revenue of $954.61M (+4.7% Y/Y) beats by $44.2M . Total net product revenues of $827 million in the second quarter (Q2'23) (+25% Y/Y) Jakafi (ruxoli...
Total net product revenues of $827 million in the second quarter (Q2'23) (+25% Y/Y) Jakafi ® (ruxolitinib) net product revenues of $682 million (+14% Y/Y) in Q2'23; raising the bottom end of full year guidance to a new range of $2.58 - $2.63 billion for FY 2023 Opzelura ...
Initial study in the neoadjuvant setting designed to assess RP1 in combination with the small molecule, oral PD-L1 inhibitor, INCB99280 Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic...
2023-07-31 13:10:06 ET Incyte ( NASDAQ: INCY ) is scheduled to announce Q2 earnings results on Tuesday, August 1st, before market open. The consensus EPS Estimate is $0.87 (-13.9% Y/Y) and the consensus Revenue Estimate is $910.41M (-0.1% Y/Y). Over the last 2 years, I...
2023-07-28 05:31:08 ET Summary Arcutis has launched Zoryve, a topical cream for the treatment of psoriasis, and is focused on transitioning to a commercial-stage company. The company has made progress with major pharmacy benefit managers and positioned Zoryve to be highly accessib...
2023-07-25 10:44:53 ET Incyte: Growing Strong But Overhyped Incyte: The Jakafi Company Branching Out - Baby Steps For further details see: Incyte a new buy at Citi on Opzelura performance
Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease PR Newswire – Trial met its primary endpoint across all cohorts with an overall response rate (ORR) of 74% at a dose of 0.3 mg/kg admi...
2023-07-11 17:08:02 ET Gainers: Incyte ( NASDAQ: INCY ) +4% . Veracyte ( VCYT ) +4% . Kronos ( KRON ) +3% . Applied Optoelectronics ( AAOI ) +3% . GoodRx ( GDRX ) +3% . Losers: Silk Road ( SI...
News, Short Squeeze, Breakout and More Instantly...
2024-07-12 10:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 11:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 06:15:05 ET BMO Capital analyst issues UNDERPERFORM recommendation for INCY on July 2, 2024 04:26AM ET. The previous analyst recommendation was Market Perform. INCY was trading at $60.87 at issue of the analyst recommendation. The overall analyst consensus : B...